Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06206941 · ClinicalTrials.gov registry record
IMmunotherapy: Prospective Assessment of Cannabis Treatment in Cancer
A clinical trial of Cancer, sponsored by State University of New York at Buffalo.
- Recruiting
- Registry status
- 450
- Enrollment target
- 2
- Study locations
NCT06206941: Recruiting study of Cancer, sponsored by State University of New York at Buffalo.
NCT06206941 is a study of Cancer that is actively recruiting participants, run by State University of New York at Buffalo. The registered enrollment target is 450 participants, below the 3,490-participant average among 615 other Cancer trials with a reported enrollment target (87% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06206941, a study of Cancer, is actively recruiting participants, sponsored by State University of New York at Buffalo.
- RECRUITING
- Registry status
- 450 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this research is to assess how patients with cancer being treated with Immune Checkpoint Inhibitors (ICI) manage symptoms related to cancer and/or its treatment. Patients use a variety of ways to manage symptoms including traditional and alternative treatments including cannabis, acupuncture, etc. This research will have an important impact on our knowledge of cancer symptom management, and ultimately improve patient care and safety. Participants will complete online surveys and 7 days of ecological momentary assessments at 0, 1, 2, 4, 6, 9 and 12 month to compare the cannabis users and non cannabis users symptoms.
Primary Outcome
Pain interference with daily life and enjoyment on a 5 item scale of not at all to very much. Higher score indicates worse outcome.
Conditions Studied
Study Locations (2)
Oregon
- Oregon Health and Science University - Portland
Pennsylvania
- Thomas Jefferson University - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 450 participants |
| Start Date | 2025-01-02 |
| Est. Completion | 2027-12-31 |
What NCT06206941 shows while recruiting
NCT06206941 is an observational study that tracks outcomes without assigning an intervention. The registered 450 participants enrollment target is mid-sized for trials with a published cap, below the 3,490-participant average among 615 other Cancer trials with a reported enrollment target (87% lower).
The record links to 1 condition, with Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT06206941 reports a single indexed study location in Oregon, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06206941 about?
NCT06206941 is a clinical study titled "IMmunotherapy: Prospective Assessment of Cannabis Treatment in Cancer". The purpose of this research is to assess how patients with cancer being treated with Immune Checkpoint Inhibitors (ICI) manage symptoms related to cancer and/or its treatment. Patients use a variety of ways to manage symptoms including traditional and alternative treatments including cannabis, acup...
What is the current status of trial NCT06206941?
This trial is currently recruiting. The enrollment target is 450 participants. The study started on 2025-01-02. Estimated completion is 2027-12-31.
What conditions does trial NCT06206941 study?
This clinical trial studies the following conditions: Cancer.
Who is sponsoring clinical trial NCT06206941?
This trial is sponsored by State University of New York at Buffalo, which has 243 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06206941 being conducted?
This trial has 2 study locations across Oregon, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06206941's enrollment target sits among peer trials
450 141st of 615 higher than 475 of 615 other Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Registry Study to Evaluate the Clinical Outcome of Cancer Patients and Benign Diseases Treated with Radiation
RECRUITING
-
Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients
RECRUITING · Phase 2
-
IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)
RECRUITING · NA
-
A Natural History Study of Metabolic Sizing in Health and Disease
RECRUITING
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
Long-Term Follow-Up of Recipient of Gene Transfer Research
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00515060 · 450 participants
Psychophysical Studies of Cancer Therapy Pain
- NCT01257269 · 450 participants
Genotype and Phenotype Correlation in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome)
- NCT03047161 · 450 participants
Electrophysiology of Fetal Arrhythmia
- NCT03269630 · 450 participants
New Orleans Pulmonary Hypertension Biobank
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI